• Explore /
  • Poster
  • / Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.

Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.

Abstract Video & Slides Poster

Authors

null

Jung-Min Lee

National Cancer Institute, Bethesda, MD

Jung-Min Lee , Richard G. Moore , Sharad A. Ghamande , Min S. Park , John Paul Diaz , Julia A. Chapman , James Erasmus Kendrick IV, Brian M. Slomovitz , Krishnansu Sujata Tewari , Elizabeth S. Lowe , Tsveta Milenkova , Sanjeev Kumar , Mike Dymond , Iwanka Kozarewa , Joyce F. Liu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02889900

Citation

J Clin Oncol 38: 2020 (suppl; abstr 6056)

DOI

10.1200/JCO.2020.38.15_suppl.6056

Abstract #

6056

Poster Bd #

227

Abstract Disclosures

Similar Posters

First Author: Joyce Liu

First Author: Helene Blons

First Author: Domenica Lorusso

First Author: Yoo Na Kim